Key facts
- Bobcatbio’s last known valuation is $51.0M (Feb 2025).
- It has raised $32.4M across 1 recorded rounds; the latest was Early Stage VC ($5.3M) in Feb 2025.
- Notable investors include National Institutes of Health, SeedFolio, BioAdvance Capital (Conshohocken), Biolocity, Bios Partners — 8 tracked in total.
- Bobcatbio has filed 1 Form D with the SEC, most recently Mar 2025 ($5.3M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Bobcatbio
Funding rounds
1 roundsAbout Bobcatbio
Developer of cancer-specific immunotherapy designed for the treatment of solid tumors. The company employs an adoptive cell therapy approach to elicit tumor-specific T-cells, resulting in a polyclonal immune response against multiple tumor antigens to trigger a robust immune attack on solid tumors and lymphomas, enabling the medical community to improve treatment outcomes related to cancer and cancer patients to receive potent, repeatable treatments that drive systemic tumor elimination.
- Sector
- Healthcare
- HQ
- PA
- Founded
- 2020
- Employees
- 8
- Website
- bobcatbio.com/
- Ownership
- Privately Held (backing)
Bobcatbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bobcatbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bobcatbio in its N-PORT filings yet. We sweep new filings monthly.